Abstract:Recent studies in patients with psychotic disorders or prolactinomas suggest that increased prolactin levels may have negative effects on cognition. Most previous studies including patients with psychotic disorders are cross-sectional, and longitudinal studies are lacking. We aimed to conduct an observational, prospective study to explore whether prolactin levels during the first year of treatment are associated with changes in cognitive tasks. Our hypothesis would be that those patients with increased prolactin levels would show a poorer cognitive outcome than those patients with lower prolactin levels. We studied 60 patients (24.5 ± 6.8 years; 36% women) with a first episode psychosis (FEP) attending the Early Psychosis Programme from two institutions (Parc Taulí Hospital Universitari, Sabadell, Spain; Hospital Universitari Institut Pere Mata). Ethical approval was obtained from the local Ethics Committees of both institutions. Clinical diagnoses for a FEP were generated with the OPCRIT checklist v.4.0 after a semistructured interview by a psychiatrist. The MATRICS Consensus Cognitive Battery (MCCB) was administered to explore neuropsychological functioning at two-time points (baseline, 1 year). The MCCB contains 10 tests to measure cognitive performance in 7 cognitive domains. Three fasting blood samples (baseline, 6 months, 12 months) were obtained in the morning between 8:30 h and 9:30 h in resting conditions, to determine unstimulated plasma prolactin. Serum prolactin levels were determined with immunoassays standardized against the 3rd International Reference Standard 84/500. Statistical analyses were performed with SPSS version 21.0. As prolactin levels might be increased by stress, particularly at the onset of the FEP, we calculated mean prolactin levels over the follow-up period taking into account prolactin values at 6 and 12 months. A general linear model for repeated measures was performed in order to test whether longitudinal changes in cognitive tasks differed by mean prolactin levels. All analyses were adjusted for gender. A p value < 0.05 (two-tailed) was considered to be significant. For descriptive purposes, patients in the fourth quartile for serum prolactin (>47.8 ng/ml for men; >54.3 ng/ml for women) where compared with those with lower prolactin levels. Patients improved in all 10 MCCB cognitive tasks one year later (p<0.05 for all tasks). When exploring the interaction between time x prolactin in the GLM analyses, significant interactions were found for three cognitive tasks related with processing speed (BACS-SC [F= 5.9, p= 0.018]; Fluency [F= 5.6, p= 0.022]) and reasoning and problem solving (NAB mazes [F= 4.8, p= 0.033]). Percent change over the follow-up period in these cognitive tasks was greater for patients with lower prolactin levels, when compared to those in the highest quartile: BACS-SC (11.8% vs 0.6%), Fluency (8.5% vs -7.4%) and NAB mazes (10.7% vs -1.1%). Our study is in accordance with previous cross-sectional studies reporting a negative effect of prolactin levels on cognition and adds new information with a prospective design. A limitation of our study is that patients were treated with different antipsychotics based on the clinical routine practice. Antipsychotic-induced hyperprolactinaemia, which is caused by tuberoinfundibular blockade of D2 receptors, may be reflecting the blockade of D2 receptors in other dopaminergic pathways (striatum and mesocortical pathways) that may also affect cognitive abilities. Further clinical trials are needed to reduce the heterogeneity of the treatment effects and to confirm the potential negative effects of prolactin on cognitive abilities.

Dynamics of Prolactin and Hormones of the Hypothalamic-Pituitary Thyroid Axis in Patients with Schizophrenia

A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients

Effects of paliperidone extended-release tablets (paliperidoneer) and olanzapine on metabolic profile, weight, insulin resistance and beta-cell function in schizophrenic patients: a randomized 12-week study

The Relationships Between Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients With Schizophrenia Under Olanzapine Treatment

The Effects of Antipsychotics on Serum Prolactin in the First-Episode Schizophrenia Patients

Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia

Cerebral Computed Tomographic Findings in Schizophrenia: Relationship to Second-Generation Antipsychotics and Hyperprolactinemia

Thyroid hormone and sex hormone levels and influencing factors inlong-term schizophreniainpatients

Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode

Prolactin level changes according to atypical antipsychotics use: a study based on Clinical Data Warehouse

[Hyperprolactinemia in mentally ill patients]

F87. SERUM PROLACTIN LEVELS AND COGNITIVE OUTCOME IN FIRST EPISODE PSYCHOSIS: A PROSPECTIVE 1-YEAR FOLLOW-UP STUDY

Prolactin Levels in Male Schizophrenic Patients Treated with Risperidone and Haloperidol: a Double-Blind and Randomized Study

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia

Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis

Factors influencing prolactin levels in chronic long-term hospitalized schizophrenic patients with co-morbid type 2 diabetes mellitus

Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis

Current guidelines and their recommendations for prolactin monitoring in psychosis

Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis

Integrating machine learning with electronic health record data to facilitate detection of prolactin level and pharmacovigilance signals in olanzapine-treated patients

Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study